Cost-effectiveness of tezepelumab in Canada for severe asthma.

Mara HabashHannah GuiangIrvin MayersAnna QuintonVivian VuongAidan DineenSumeet SinghDanny Gibson Adrian P Turner

Published in: Journal of medical economics (2023)

Tezepelumab provided additional life years and QALYs at additional cost compared with SoC in Canada. In addition, tezepelumab dominated (i.e., more effective, less costly) the other currently reimbursed biologics.

Keyphrases